A retrospective analysis of human papillomavirus (HPV) prevalence and genotype distribution among 25,238 women in Shanghai,China revealed the limitations of current HPV-based screening and HPV vaccine |
| |
| Institution: | 1. Department of Obstetrics and Gynecology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, China;2. Department of Gynecology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai 201204, China;1. Department of Public Health, and Department of Endocrinology of the Children''s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children’s Health, Hangzhou 310058, China;2. Department of Public Health, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China;3. Department of Public Health, Fourth Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China;1. CONACYT - Instituto Nacional de Cancerología, Mexico City, Mexico;2. Dirección de Investigación, Hospital General de México “Dr. Eduardo Liceaga”, Mexico City, Mexico;3. Dirección de Investigación, Instituto Nacional de Cancerología, Mexico City, Mexico;4. Departamento de Tumores Mamarios, Instituto Nacional de Cancerología, Mexico City, Mexico;5. Servicio de Oncología, Hospital General de México “Dr. Eduardo Liceaga”, Mexico City, Mexico;6. Departmento de Tumores Ginecológicos, Instituto Nacional de Cancerología, Mexico City, Mexico;7. Departmento de Tumores Urológicos, Instituto Nacional de Cancerología, Mexico City, Mexico;8. Servicio de Urología, Hospital General de México “Dr. Eduardo Liceaga”, Mexico City, Mexico;9. Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México and Instituto Nacional de Cancerología, Mexico City, Mexico;1. Unit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark;2. Unit of Diet, Cancer and Health, Danish Cancer Society Research Center, Copenhagen, Denmark;3. Statistics and Data Analysis, Danish Cancer Society Research Center, Copenhagen, Denmark;4. Department of Gynecology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark;1. Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA, USA;2. Oak Ridge Institute for Science and Education, Oak Ridge, TN, USA;3. Cyberdata Technologies, Inc., Herndon, VA, USA;4. Division of Cancer Control and Population Sciences, University of Puerto Rico Comprehensive Cancer Center, San Juan, PR, USA;5. Population and Quantitative Health Sciences, University of Massachusetts Chan Medical School, Worcester, MA, USA;6. John A Burns School of Medicine, University of Hawai‘i at Mānoa, Honolulu, HI, USA;7. Division of Chronic Disease and Prevention, US Virgin Islands Department of Health, St. Thomas, USVI, USA;1. Johns Hopkins Medicine, Department of Dermatology, Baltimore, MD, USA;2. University of Texas Southwestern Medical Center, Department of Dermatology, Dallas, TX, USA;3. Case Western Reserve University School of Medicine/University Hospitals Cleveland Medical Center, Department of Dermatology, Cleveland, OH, USA;1. Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada;2. Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada;3. Department of Surgery, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada |
| |
| Abstract: | BackgroundTo determine the human papillomavirus (HPV) type-specific prevalence and distribution among women with various age and cervical lesions in Shanghai, China. And to evaluate the carcinogenicity of different high-risk HPV (HR-HPV) and the efficacy of HR-HPV testing and HPV vaccine.MethodsThe clinical data from 25,238 participants who received HR-HPV testing (HPV GenoArray test kit, HybriBio Ltd) at the Affiliated Hospital of Tongji University from 2016 to 2019 were reviewed and analyzed using SPSS (version 20.0, Tongji University, China).ResultsThe overall prevalence of HPV was 45.57% in the study population, of which 93.51% were found HR-HPV infection. The three most prevalent HR-HPV genotypes were HPV 52 (22.47%), 16 (16.4%) and 58 (15.93%) among HPV-positive women, and HPV 16 (43.30%), 18 (9.28%) and 58 (7.22%) in women with histologically confirmed cervical cancer (CC). 8.25% of CC were found to be HPV negative. Only 83.51% of CC cases were related to the HPV genotypes covered by nine-valent HPV vaccine. HPV prevalence and genotype distribution varied with age and cervical histology. The odds ratios (OR) of HR-HPV for CC were also different, among which the top three types were HPV 45 OR= 40.13, 95% confidence intervals (CI) 10.37–155.38], 16 (OR=33.98, 95%CI 15.90–72.60) and 18 (OR=21.11, 95%CI 8.09–55.09). The increase in the types of HPV infection did not increase the risk of CC correspondingly. As the primary cervical screening method, HR-HPV testing showed the high sensitivity (93.97%, 95%CI 92.00–95.49) but low specificity (42.82%, 95%CI 41.81–43.84).ConclusionsOur study provide the comprehensive epidemiological data on HPV prevalence and genotype distribution among Shanghai women with various cervical histology, which can not only serve as a significant reference for clinical practice, but also implicated the need of more effective CC screening methods and HPV vaccine covering more subtypes. |
| |
| Keywords: | Human papillomavirus Prevalence Distribution Cervical cancer Cervical intraepithelial neoplasia |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
